Efgartigimod IV or Efgartigimod PH20 SC clinical trials

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

This study looks at the long-term safety of two forms of a drug called efgartigimod for children and teenagers with a muscle weakness condition called generalised Myasthenia Gravis (gMG). Participants are those who have previously taken part in other efgartigimod studies.